Product Information
SUMATRIPTAN 5 MG NASAL SPRAY is a generic product labeled by Lannett Company Inc., priced at $17.0386 per EA under NDC 00527181843. Its NADAC has been published 518 times since Nov 2, 2016.
FDA first approved this application on Feb 19, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/.1mL
Manufacturer
Lannett Company Inc.NDC
00527181843
Classification
Generic
Dosage Form
SPRAY
Route
NASAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTANApproval Type
Generic (ANDA)
FDA Application
ANDA204841FDA Approved
2/19/2016
TE Code
AB
On Market Since
2/19/2016
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has been published 518 times since Nov 2, 2016, and over the history we have for it it has declined 65.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $17.0386 per EA |
|---|---|
| All-time high | $55.1350 (Feb 14, 2018) |
| All-time low | $17.0386 (Sep 23, 2026) |
| 52-week high | $22.5444 |
| 52-week low | $17.0386 |
| Median price | $38.7967 |
| Average price | $38.0042 |
| Largest weekly change | +44.0% (Aug 21, 2024) |
| Weeks tracked | 518 |
| Tracking since | Nov 2, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Sumatriptan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lannett Company Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN 5 MG NASAL SPRAY?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN 5 MG NASAL SPRAY, manufactured by Lannett Company Inc., is $17.0386 per EA (NDC 00527181843), effective Sep 30, 2026.
How has the price of SUMATRIPTAN 5 MG NASAL SPRAY changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has declined 65.3%. It has been tracked across 518 weekly CMS publications since Nov 2, 2016.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN 5 MG NASAL SPRAY?
Since Nov 2, 2016, the NADAC for SUMATRIPTAN 5 MG NASAL SPRAY has ranged from a low of $17.0386 (Sep 23, 2026) to a high of $55.1350 (Feb 14, 2018), with a median of $38.7967 per EA.
Are there cheaper alternatives to SUMATRIPTAN 5 MG NASAL SPRAY?
No other NADAC-published product currently shares the active ingredient and strength of SUMATRIPTAN 5 MG NASAL SPRAY in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures SUMATRIPTAN 5 MG NASAL SPRAY?
SUMATRIPTAN 5 MG NASAL SPRAY (NDC 00527181843) is labeled by Lannett Company Inc., and CMS classifies it as a generic product.